Pasithea Therapeutics Corp.
KTTAHealthcare|Biotechnology|US
$0.58
+0.06 (+11.31%)
DCF Value
$7.85
Tangible Book / Share
$6.60
Cash / Share
$6.49
Financials
Financial Snapshot
Market Cap
$19.3M
Enterprise Value
-$26.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$21.3M
Cash & Investments
$45.7M
Net Cash
$45.7M
Free Cash Flow (TTM)
-$17.8M
Operating CF (TTM)
-$17.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$45.7M
Quarterly Burn
$4.4M
Monthly Burn
$1.5M
Est. Runway
~10.3 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $243.7K | $53.0M | $33.1M | $16.3M | $6.9M | $55.2M | $45.7M | |
| Operating Cash Flow | -$38.7K | -$3.2M | -$13.7M | -$13.4M | -$13.9M | -$15.2M | -$17.8M | |
| Free Cash Flow | -$38.7K | -$3.2M | -$13.8M | -$13.5M | -$13.9M | -$15.2M | -$17.8M | |
| Capital Expenditure | -$1.00 | -$21.5K | -$107.1K | -$34.3K | -$2.00 | $0.00 | $1.00 | |
| Financing Cash Flow | $282.3K | $55.9M | -$3.2M | -$3.7M | $4.5M | $63.5M | $56.3M |
R&D Spending
R&D (TTM)
$6.63B
R&D Intensity
—
R&D Growth vs Prior
+82996.6%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $15.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $2.7M | $8.1M | $7.2M | $8.0M | $6.63B | |
| R&D % of Revenue | — | 0.0% | — | — | — | — | — | |
| SG&A | $0.00 | $4.5M | $9.9M | $7.9M | $7.1M | $12.9M | $3.97B |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $15.1K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $17.3K | $5.1K | $0.00 | $0.00 | $0.00 | $473.0K | |
| Gross Profit | $0.00 | -$2.2K | -$5.1K | $0.00 | $0.00 | $0.00 | -$473.0K | |
| R&D | $0.00 | $0.00 | $2.7M | $8.1M | $7.2M | $8.0M | $6.63B | |
| SG&A | $0.00 | $4.5M | $9.9M | $7.9M | $7.1M | $12.9M | $3.97B | |
| Operating Income | -$61.5K | -$4.5M | -$12.6M | -$16.0M | -$14.2M | -$20.9M | -$24.0M | |
| Interest Expense | $0.00 | $508.00 | $102.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$61.5K | -$2.2M | -$11.7M | -$15.5M | -$13.9M | -$20.4M | -$21.3M | |
| Net Income | -$61.5K | -$2.2M | -$13.9M | -$16.0M | -$13.9M | -$20.4M | -$21.3M | |
| EPS (Diluted) | -0.06 | -4.20 | -10.34 | -13.01 | -12.69 | -2.91 | -2.46 | |
| EBITDA | $0.00 | -$2.2M | -$11.7M | -$15.3M | -$13.6M | -$20.2M | -$23.3M | |
| Shares Out. (M) | 0.69 | 0.52 | 1.26 | 1.23 | 1.10 | 7.03 | 7.03 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $243.7K | $53.0M | $33.1M | $16.3M | $6.9M | $55.2M | $45.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $248.0K | $53.3M | $34.1M | $16.7M | $7.4M | $56.5M | $48.2M | |
| Total Assets | $248.0K | $53.3M | $45.2M | $26.1M | $16.1M | $60.2M | $51.7M | |
| Total Current Liabilities | $6.6K | $447.3K | $1.9M | $2.6M | $1.1M | $5.0M | $1.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.6K | $1.9M | $2.7M | $2.7M | $1.3M | $5.0M | $1.9M | |
| Stockholders' Equity | $241.4K | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M | $49.8M | |
| Retained Earnings | -$41.0K | -$2.2M | -$19.4M | -$35.3M | -$49.6M | -$70.0M | -$78.2M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$38.7K | -$3.2M | -$13.7M | -$13.4M | -$13.9M | -$15.2M | -$17.8M | |
| Capital Expenditure | -$1.00 | -$21.5K | -$107.1K | -$34.3K | -$2.00 | $0.00 | $1.00 | |
| Free Cash Flow | -$38.7K | -$3.2M | -$13.8M | -$13.5M | -$13.9M | -$15.2M | -$17.8M | |
| Investing Cash Flow | $0.00 | -$21.5K | -$2.9M | $399.0K | $0.00 | $11.0K | $0.00 | |
| Financing Cash Flow | $282.3K | $55.9M | -$3.2M | -$3.7M | $4.5M | $63.5M | $56.3M | |
| Issuance of Stock | $282.3K | $50.2M | $0.00 | $0.00 | $4.5M | $64.0M | $56.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$3.7M | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $471.3K | $835.1K | $592.3K | $773.7K | $297.5K | $469.3M | |
| Net Change in Cash | $243.7K | $52.7M | -$19.9M | -$16.8M | -$9.4M | $48.3M | $38.5M |
Dilution Tracker
Shares outstanding grew 920.6% over 5 years — significant dilution
Shares Outstanding
33M
5-Year Share Growth
+920.6%
Stock Issuance (TTM)
$56.5M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.69 | 0.52 | 1.26 | 1.23 | 1.10 | 7.03 | 7.03 | |
| Change vs Prior % | — | -24.5% | 142.6% | -2.8% | -10.6% | 541.5% | 0.0% | |
| Stock Issuance | $282.3K | $50.2M | $0.00 | $0.00 | $4.5M | $64.0M | $56.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$3.7M | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $471.3K | $835.1K | $592.3K | $773.7K | $297.5K | $469.3M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | -14.7% | — | — | — | — | — | |
| Operating Margin % | — | -29925.7% | — | — | — | — | — | |
| Net Margin % | — | -14430.5% | — | — | — | — | — | |
| EBITDA Margin % | — | -14418.0% | — | — | — | — | — | |
| FCF Margin % | — | -21216.0% | — | — | — | — | — | |
| ROE % | -25.5% | -4.2% | -32.8% | -68.2% | -94.1% | -37.0% | -49.5% | |
| ROA % | -24.8% | -4.1% | -30.8% | -61.1% | -86.6% | -33.9% | -41.2% | |
| ROIC % | -25.5% | -8.5% | -29.0% | -67.8% | -95.4% | -37.7% | -48.0% | |
| R&D / Revenue % | — | 0.0% | — | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | -130.2% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -7232.0% | -179.3% | -26.9% | 10.8% | -46.4% | |
| Net Income | 0.0% | -3435.6% | -541.2% | -14.5% | 12.9% | -46.9% | |
| EPS (Diluted) | 0.0% | -6970.7% | -146.2% | -25.8% | 2.5% | 77.1% | |
| Operating Cash Flow | 0.0% | -8104.0% | -331.3% | 1.9% | -3.7% | -9.3% | |
| Free Cash Flow | 0.0% | -8159.4% | -331.8% | 2.5% | -3.4% | -9.3% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 203.9% | -11.1% | 10.9% | |
| SG&A Expense | 0.0% | 0.0% | 120.2% | -20.6% | -10.5% | 82.6% | |
| Total Assets | 0.0% | 21403.9% | -15.3% | -42.2% | -38.5% | 275.0% | |
| Book Value / Share | 0.0% | 28113.0% | -65.9% | -43.3% | -29.3% | -41.8% | |
| Debt | 0.0% | 0.0% | 0.0% | -83.8% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | -24.5% | 142.6% | -2.8% | -10.6% | 541.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.08
10Y Low / Med / High0.16 / 0.38 / 203.23
EV/EBITDA1.13
10Y Low / Med / High0.26 / 1.40 / 15.91
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$7.85
Tangible Book / Share
$6.60
Net Current Assets / Share
$1.39
Graham Net-Net
$6.23
Cash / Share
$6.49
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1198.65 | -8.43 | -1.24 | -0.57 | -0.25 | -0.44 | -0.24 | |
| P/S Ratio | 0.00 | 1222.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 203.23 | 0.36 | 0.38 | 0.39 | 0.23 | 0.16 | 0.08 | |
| EV/EBITDA | 0.00 | 15.91 | 1.40 | 0.47 | 0.26 | 2.28 | 1.13 | |
| EV/Revenue | 0.00 | -2293.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
3.64
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$5.3M | -$3.2M | -$3.9M |
| EPS | $-0.76 | $-0.46 | $-0.55 |
| # Analysts (EPS) | 1 | 1 | 1 |